AI Article Synopsis
- A mid-infrared source emitting at approximately 3 μm is utilized to assess hydration levels in porcine cornea.
- The Er(3+):YAG emission focuses on vibrational modes in water molecules, specifically around 3300 cm(-1).
- This method is particularly sensitive to variations in water content within the top 10 μm of corneal tissue.
Article Abstract
A mid-infrared (IR) source at ∼ 3 μm radiation is used as a probe to measure hydration in porcine cornea. Since the Er(3+):YAG emission targets vibrational modes (around 3300 cm(-1)) in the H2O molecule, it is highly sensitive to changes in water content in the first ∼ 10 μm of the corneal tissue.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jtos.2014.08.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dengue virus IgG and neutralizing antibody titers measured with standard and mature viruses are protective.
Nat Commun
January 2025
Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
The standard dengue virus (DENV) neutralization assay inconsistently predicts dengue protection. We compare how IgG ELISA, envelope domain III (EDIII), or non-structural protein 1 (NS1) binding antibodies, and titers from plaque reduction neutralization tests (PRNTs) using standard and mature viruses are associated with dengue. The ELISA measures IgG antibodies that bind to inactivated DENV1-4.
View Article and Find Full Text PDFExtracellular Histones Profiles of Pediatric H3K27-Altered Diffuse Midline Glioma.
Mol Diagn Ther
January 2025
Department of Stem Cell Biology and Transplantology, Research Institute of the Medical University of Varna, Varna, Bulgaria.
Background: Diffuse midline glioma, H3 K27-altered (DMG) is a fatal tumour that arises in the midline structures of the brain. When located in the pons, it is more commonly referred to as diffuse intrinsic pontine glioma (DIPG). DMG/DIPG is usually diagnosed when children are < 10 years, and it has a median overall survival of < 12 months after diagnosis.
View Article and Find Full Text PDFMolecular landscape of the overlap between Alzheimer's disease and somatic insulin-related diseases.
Alzheimers Res Ther
October 2024
Department of Cognitive Neuroscience, Radboud University Medical Center, Nijmegen, The Netherlands.
Alzheimer's disease (AD) is a multifactorial disease with both genetic and environmental factors contributing to its etiology. Previous evidence has implicated disturbed insulin signaling as a key mechanism that plays a role in both neurodegenerative diseases such as AD and comorbid somatic diseases such as diabetes mellitus type 2 (DM2). In this study, we analysed available genome-wide association studies (GWASs) of AD and somatic insulin-related diseases and conditions (SID), i.
View Article and Find Full Text PDFp16-dependent increase of PD-L1 stability regulates immunosurveillance of senescent cells.
Nat Cell Biol
August 2024
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
The accumulation of senescent cells promotes ageing and age-related diseases, but molecular mechanisms that senescent cells use to evade immune clearance and accumulate in tissues remain to be elucidated. Here we report that p16-positive senescent cells upregulate the immune checkpoint protein programmed death-ligand 1 (PD-L1) to accumulate in ageing and chronic inflammation. We show that p16-mediated inhibition of cell cycle kinases CDK4/6 induces PD-L1 stability in senescent cells via downregulation of its ubiquitin-dependent degradation.
View Article and Find Full Text PDFSafety and effectiveness of disease-modifying therapies after switching from natalizumab.
Mult Scler
July 2024
Neurology Institute and MS Center, Harley Street Medical Center, Abu Dhabi, United Arab Emirates.
Article Synopsis
- The study focuses on finding the best disease-modifying therapies (DMTs) to switch to after stopping natalizumab (NTZ) due to John Cunningham virus (JCV) antibody positivity.
- A multicenter study involved 321 relapsing-remitting multiple sclerosis patients, comparing the outcomes of those who switched to rituximab/ocrelizumab, fingolimod, and alemtuzumab.
- Results indicated that patients switching to rituximab/ocrelizumab or alemtuzumab experienced lower relapse rates and less disability progression, making them more effective options than fingolimod.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!